Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ramesh Ashwath

Gastroenterology Brandon, FL Medical Doctor

NPI 1386698074 CMS profile 62289

1130 Kyle Wood Ln, Brandon, FL 33511

Open in the dashboard

General payments

$8,289

310 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ramesh Ashwath of Brandon, FL is reported in the CMS Open Payments database as having received $8,289 across 310 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $791 37
2024 General $1,175 46
2023 General $1,474 53
2022 General $1,664 51
2021 General $1,378 57
2020 General $330 18
2019 General $1,477 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ramesh Ashwath
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Ramesh Ashwath were reported at $791. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Ramesh Ashwath Gastroenterology median Middle half National median
2019 $1,477 $417 $126–$1,100 $163
2020 $330 $224 $74–$624 $114
2021 $1,378 $352 $106–$1,054 $132
2022 $1,664 $448 $129–$1,270 $149
2023 $1,474 $533 $150–$1,390 $160
2024 $1,175 $605 $160–$1,606 $164
2025 $791 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,673 131 payments
  2. Janssen Biotech, Inc. $662 24 payments
  3. Gilead Sciences, Inc. $479 22 payments
  4. Medtronic, Inc. $472 4 payments
  5. Janssen Scientific Affairs, LLC $367 3 payments
  6. Aimmune Therapeutics, Inc. $336 12 payments
  7. Celgene Corporation $305 15 payments
  8. Pfizer Inc. $293 17 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $243 13 payments
  10. Ethicon US, LLC $242 4 payments
  11. Other $2,219 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,068 305 payments
  2. Education $221 5 payments
Products named General payments · program years 2019–2025
  1. STELARA $1,010 26 payments
  2. CREON $757 48 payments
  3. LINZESS $592 37 payments
  4. SKYRIZI $571 23 payments
  5. HUMIRA $368 24 payments
  6. RINVOQ $334 17 payments
  7. GI Genius $311 2 payments
  8. MAVYRET $308 18 payments
  9. ZEPOSIA $305 15 payments
  10. ZENPEP $299 11 payments
  11. Other $3,413 125 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

600

Median for Internal Medicine: 777

Drug cost

$209,991

Median for Internal Medicine: $73,373

Branded share of claims

27.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 29 $102,023
Linzess Linaclotide Brand 68 $42,595
Zenpep Lipase/Protease/Amylase Brand 15 $37,763
Motegrity Prucalopride Succinate Brand 20 $12,770
Mesalamine Generic 20 $4,193
Colestipol Hcl Generic 55 $3,822
Cholestyramine Cholestyramine (With Sugar) Brand 20 $1,517
Omeprazole Generic 136 $1,322
Budesonide Dr Budesonide Brand 14 $1,296
Famotidine Generic 107 $894

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$187,868

Medicare's payments for the services billed

Medicare patients

592

Average age 74

Services billed

1,781

342 women, 250 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Ischemic heart disease 42%
Diabetes 40%
Chronic kidney disease 39%
Depression 31%
COPD 28%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $191
$191 15 —
GIMOTI
  • EVOKE PHARMA, INC. $118
$118 — —
RINVOQ
  • AbbVie, Inc. $78
$78 — —
SKYRIZI
  • AbbVie, Inc. $70
$70 — —
STELARA
  • Janssen Biotech, Inc. $42
$42 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

310 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record